Analysts think VTYX stock price could increase by 719%
Mar 25, 2025, 11:25 AM
-15.33%
What does VTYX do
Ventyx Biosciences, a San Diego-based clinical-stage biopharmaceutical company, develops small molecule therapeutics for autoimmune diseases with a pipeline including VTX002, VTX958, VTX2735, and VTX3232. The company went public on October 21, 2021, and employs 74 people.
7 analysts think VTYX stock price will increase by 718.98%. The current median analyst target is $11.22 compared to a current stock price of $1.37. The lowest analysts target is $2.02 and the highest analyst target is $22.05.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
